Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway.

[1]  John I. Gallin,et al.  Inflammation: Basic Principles and Clinical Correlates , 1992 .

[2]  B. Zweiman,et al.  In vivo antigen-induced cutaneous mediator release: simultaneous comparisons of histamine, tryptase, and prostaglandin D2 release and the effect of oral corticosteroid administration. , 1990, The Journal of allergy and clinical immunology.

[3]  D. Broide,et al.  Airway levels of mast cell-derived mediators in exercise-induced asthma. , 1990, The American review of respiratory disease.

[4]  G. Gleich.  The eosinophil and bronchial asthma: current understanding. , 1990, The Journal of allergy and clinical immunology.

[5]  R. Naclerio,et al.  Major basic protein and eosinophil-derived neurotoxin concentrations in nasal-lavage fluid after antigen challenge: effect of systemic corticosteroids and relationship to eosinophil influx. , 1989, The Journal of allergy and clinical immunology.

[6]  A. Sheffer,et al.  Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome , 1989, The Journal of experimental medicine.

[7]  C. Heusser,et al.  Production of the haemopoietic growth factors GM-CSF and interleukin-3 by mast cells in response to IgE receptor-mediated activation , 1989, Nature.

[8]  W. Paul,et al.  Mast cell lines produce lymphokines in response to cross-linkage of FcεRI or to calcium ionophores , 1989, Nature.

[9]  D. Proud,et al.  Inhibition of human bronchial kallikrein in asthma. , 1989, The American review of respiratory disease.

[10]  S. Holgate,et al.  Cellular events in the bronchi in mild asthma and after bronchial provocation. , 1989, The American review of respiratory disease.

[11]  L. Lichtenstein,et al.  Dexamethasone does not inhibit the release of mediators from human mast cells residing in airway, intestine, or skin. , 1989, The American review of respiratory disease.

[12]  J. Nadel,et al.  Mast cell tryptase causes airway smooth muscle hyperresponsiveness in dogs. , 1989, The Journal of clinical investigation.

[13]  R. Naclerio,et al.  The influx of inflammatory cells into nasal washings during the late response to antigen challenge. Effect of systemic steroid pretreatment. , 1988, The American review of respiratory disease.

[14]  B. Zweiman,et al.  Release of histamine and tryptase in vivo after prolonged cutaneous challenge with allergen in humans. , 1988, Journal of immunology.

[15]  S. Wenzel,et al.  Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma. , 1988, The American review of respiratory disease.

[16]  R. Naclerio,et al.  Basophil influx occurs after nasal antigen challenge: effects of topical corticosteroid pretreatment. , 1988, The Journal of allergy and clinical immunology.

[17]  T. Casale,et al.  Direct evidence of a role for mast cells in the pathogenesis of antigen-induced bronchoconstriction. , 1987, The Journal of clinical investigation.

[18]  R. Naclerio,et al.  Effect of short-term systemic glucocorticoid treatment on human nasal mediator release after antigen challenge. , 1987, The Journal of clinical investigation.

[19]  H. S. Earl,et al.  Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. , 1987, The New England journal of medicine.

[20]  T. Casale,et al.  Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with methacholine bronchial hyperresponsiveness. , 1987, The Journal of clinical investigation.

[21]  L. Lichtenstein,et al.  Dexamethasone inhibits the antigen-induced contractile activity and release of inflammatory mediators in isolated guinea pig lung tissue. , 1987, The American review of respiratory disease.

[22]  J. Murray,et al.  Release of prostaglandin D2 into human airways during acute antigen challenge. , 1986, The New England journal of medicine.

[23]  G. Gleich,et al.  The eosinophil and the pathophysiology of asthma. , 1986, The Journal of allergy and clinical immunology.

[24]  S. Wenzel,et al.  Immunoassay of tryptase from human mast cells. , 1986, Journal of immunological methods.

[25]  D. Lenihan,et al.  Increased biosynthesis of platelet-activating factor in activated human eosinophils. , 1984, The Journal of biological chemistry.

[26]  J. Harley,et al.  Distinctive cationic proteins of the human eosinophil granule: major basic protein, eosinophil cationic protein, and eosinophil-derived neurotoxin. , 1983, Journal of immunology.

[27]  S. Wasserman,et al.  Modulation of rat serosal mast cell biochemistry by in vivo dexamethasone administration. , 1983, Journal of immunology.

[28]  S. Peters,et al.  Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. , 1983, The Journal of clinical investigation.

[29]  G. Gleich,et al.  Activation of basophil and mast cell histamine release by eosinophil granule major basic protein , 1983, The Journal of experimental medicine.

[30]  F. Hirata,et al.  Biochemical analysis of glucocorticoid-induced inhibition of IgE-mediated histamine release from mouse mast cells. , 1982, Journal of immunology.

[31]  K. E. Holley,et al.  IDENTIFICATION BY IMMUNOFLUORESCENCE OF EOSINOPHIL GRANULE MAJOR BASIC PROTEIN IN LUNG TISSUES OF PATIENTS WITH BRONCHIAL ASTHMA , 1982, The Lancet.

[32]  R. Schleimer,et al.  Inhibition of basophil histamine release by anti-inflammatory steroids , 1981, Nature.

[33]  R. Schooley,et al.  Elevated serum levels of the eosinophil granule major basic protein in patients with eosinophilia. , 1981, The Journal of clinical investigation.

[34]  R. Slott,et al.  Histologic studies of human skin test responses to ragweed and compound 48/80. II. Effects of corticosteroid therapy. , 1975, The Journal of allergy and clinical immunology.